Medxy AI

Neuropsychiatric Symptoms and Their Impact on Daily Functioning in Cognitively Unimpaired Older Adults

By MedXY 08/02/2025

Neuropsychiatric symptoms such as decreased motivation and emotional dysregulation significantly impair daily functioning in older adults without cognitive impairment, highlighting the need for early identification and intervention.

Wellness & Lifestyle

The Soleus Muscle: The Body’s Second Heart and Its Vital Role

By MedXY 08/02/2025

Discover the fascinating role of the soleus muscle, often called the body's second heart, in promoting circulation and overall health.

Clinical Updates Wellness & Lifestyle

Elevated Risk of Alzheimer’s Disease and Related Dementias in Transfeminine Adults: Insights from a Large Cohort Study

By MedXY 08/02/2025

Recent data reveal that transfeminine adults experience significantly higher prevalence of Alzheimer's disease and related dementias compared to matched cisgender peers, independent of gender-affirming hormone therapy, highlighting urgent needs for targeted research and care strategies.

Medical News Wellness & Lifestyle

Understanding Legionnaires’ Disease: A Public Health Concern

By MedXY 08/02/2025

Legionnaires’ disease is a severe lung infection caused by bacteria in contaminated water systems. Recent cases in NYC highlight the importance of prevention and management.

Clinical Updates Wellness & Lifestyle

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

By MedXY 08/02/2025

Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.

Medical News Wellness & Lifestyle

Declining Vaccination Rates Among US Kindergarteners: A Growing Public Health Concern

By MedXY 08/02/2025

Vaccination rates for US kindergarteners have declined for the third consecutive year, raising public health concerns. Experts attribute this trend to increased vaccine hesitancy and misinformation.

Clinical Updates Wellness & Lifestyle

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

By MedXY 08/02/2025

The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

By MedXY 08/02/2025

Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.

Clinical Updates Wellness & Lifestyle

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Neuropsychiatric Symptoms and Their Impact on Daily Functioning in Cognitively Unimpaired Older Adults

The Soleus Muscle: The Body’s Second Heart and Its Vital Role

Elevated Risk of Alzheimer’s Disease and Related Dementias in Transfeminine Adults: Insights from a Large Cohort Study

Understanding Legionnaires’ Disease: A Public Health Concern

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

Declining Vaccination Rates Among US Kindergarteners: A Growing Public Health Concern

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia